Loading clinical trials...
Loading clinical trials...
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Primary Objective: • To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas. Secondary Objectives: * To provide useful prognostic information before treatment, assess molecular response at interim time points and residual disease at the end of therapy, and identify tumor-specific mutations * Levels of cfDNA and its association with both EFS and OS in patients receiving therapy
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
MD Anderson Cancer Center
Houston, Texas, United States
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
San Antonio, Texas, United States
Start Date
February 23, 2023
Primary Completion Date
August 31, 2026
Completion Date
August 31, 2026
Last Updated
October 31, 2025
517
ESTIMATED participants
cell-free DNA
DIAGNOSTIC_TEST
Lead Sponsor
M.D. Anderson Cancer Center
NCT06263491
NCT05529069
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05139017